<SEC-DOCUMENT>0001193125-22-283958.txt : 20221114
<SEC-HEADER>0001193125-22-283958.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114100200
ACCESSION NUMBER:		0001193125-22-283958
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221111
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221381556

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d367678d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated November&nbsp;11, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d367678dex991.htm">Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;11, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d367678dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g367678g92y43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Promising Initial Clinical Data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> at SITC 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>First activity evaluation of efti as part of triple combination therapy yields promising early results </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC patients </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The triple combination therapy has been well tolerated and appears to be safe </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 11</B><B></B><B>&nbsp;November </B><B>2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces encouraging initial clinical data from the
investigator-initiated <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial has been published in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT>
is the first trial evaluating Immutep&#146;s lead product candidate, eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) as part of a triple combination therapy with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster entitled &#147;<I>Feasi<U>bility of eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein) combined with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care-therapy</FONT></FONT> in advanced <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung cancer (NSCLC). Initial results from INSIGHT 003</U></I><I>&#148;</I> provided
initial efficacy details on 11 of 14 patients currently treated with subcutaneous efti in combination with pembrolizumab and doublet chemotherapy (carboplatin and pemetrexed) delivered intravenously in 1st line NSCLC patients. Safety-related
information was provided for the 14 patients currently enrolled in the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial clinical data show that the approach is well-tolerated and
provides promising early signals of therapeutic activity with an Objective Response Rate (ORR) of 72.7% (8/11) and a Disease Control Rate (DCR) of 90.9% (10/11). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, 81.8% (9/11) of patients had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) of &lt;50%. This is generally consistent
with the overall patient population in this indication where roughly 70% of patients have a <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression level below 50%. These patients are usually less responsive to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> based therapy compared with patients having a TPS of &#8805;50%, necessitating new approaches to fight their cancers. For the 9 patients in the <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT>
trial having <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS of &lt;50%, the ORR was also a promising 66.7% (6/9) and DCR was 88.9% (8/9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof.</B>
<B>Dr.</B><B></B><B>&nbsp;Salah-Eddin Al-Batran, Scientific Lead of the INSIGHT study, noted:</B> &#147;Efti has accumulated an excellent safety profile to date, driving its high suitability for combination with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapies to address areas of unmet need for cancer patients. <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> represents the first triple combination therapy consisting of efti plus <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and chemo, and we are pleased with these promising, early results.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep&#146;s CEO Marc Voigt also added:</B> &#147;We are encouraged to see these promising initial results from
<FONT STYLE="white-space:nowrap">INSIGHT-003.</FONT> When taken in conjunction with the data reported from our other trials, they give us continued confidence in the flexibility of efti to be safely combined in various novel formats and enhance
various therapeutic approaches for multiple solid tumours. Importantly, <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> may also help to further inform the late-stage trial&nbsp;design options for efti, our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, in first line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g367678g92y43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep&#146;s CSO</B><B></B><B>&nbsp;&amp; CMO Dr Frederic Triebel, also noted</B>: &#147;This early data represents a
strong start. We have previously seen efti enhance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapy and chemotherapy, separately, and so the combination of all three therapies in <FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> is instructive. In particular, this data continues to build our understanding of efti&#146;s ability to boost the innate and adaptive immune system and provides important insights into how efti may
ultimately meet diverse NSCLC patient needs in both chemo and chemo-free settings. We look forward to seeing the data mature.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Efficacy
Results Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Table 1: ORR and DCR for <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> (data
<FONT STYLE="white-space:nowrap">cut-off</FONT> date: 14&nbsp;October 2022) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Tumour Response&#151;according to RECIST 1.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br>N(%)<br>Total&nbsp;(N=11)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Response (CR)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(0)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Response (PR)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(72.7%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable Disease (SD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(18.2%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progressive Disease (PD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(9.1%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Objective Response Rate (ORR)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(72.7%)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Disease Control Rate (DCR)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(90.9%)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination
therapy has been well tolerated and appears to be safe, with only 1 immune-related SAE (pancreatitis) relating to the study treatment (i.e. pembro/efti). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The triple combination therapy of efti in
combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy appears to be feasible and safe. Furthermore, first promising signals of therapeutic activity were detected and will
continue to be evaluated as the trial progresses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, <U>this <I>Trial in Progress</I></U> poster presentation of the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> randomized Phase IIb study of eftilagimod alpha and pembrolizumab as 1st line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma was also presented at SITC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator for the
treatment of cancer, capitalising on <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> unique characteristics to stimulate both innate and adaptive immunity. Efti binds to and activates antigen presenting cells via MHC II molecules
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g367678g92y43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">leading to expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and
monocytes. It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and HER2&#150;/HR+ metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT>
immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF at
Krankenhaus Nordwest in Frankfurt. It is being run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple combination therapy consisting of
efti in conjunction with an existing approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT>
therapy and chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to 20 patients with solid tumours will be recruited to participate in the trial. Patients will receive 30 mg subcutaneous
doses of efti every two weeks in conjunction with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy plus
chemotherapy. The trial will assess the safety, tolerability, and initial efficacy of the combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for
the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT>
fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple
clinical trials. The Company is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune
response modulation, are licensed to and being developed by Immutep&#146;s large pharmaceutical partners. Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) 679 9282; <U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g367678g92y43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g367678g92y43.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( &@#& ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $SB@#-OM?TW3W
M\N>X'F#JJ@L1]<=*ES2,I581W$L?$&FZA((H;@>8>BL"I/TSUH4TPC6A)V1J
M51J% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!EZ_J#:;I,LR?ZP_
M(GL3WJ9.R,JLN2%SBK7P_)J=TPL[R.:-0"\K C!/;'6L%"[.&-%S>C+%]:6^
MARW*W< >:9<V[1$@1XSS]<XIM*&Z*E&-%N^_0ZKPYJ+ZGI*2R',J$HY]2._Y
M$5K!W1UT9\\+LUZLV"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#D-0\7W5IXNCT=+)6A+HA;)W'<!R/S_2@#KQTH * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M%"A"#NC9 Q5FXM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P"RFJJ?"C;%?"BQX43S/#03IN9Q^M53^$O#_ <)X+O8]'\4%+QA$&5H69N
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M*J"K>Y'K5&AC)\,"&^?5<C_9@_\ LJ .NT'0H- L6M8)))%9S(S/CK@#M]*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0!WGA_\ Y%S3?^O:/_T$4 :5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 54LA'=23I+(/,;<R9&TG 'IZ 4 ,72K5%3;
M$!(C[Q(!\V<Y//OS^= !)IL3R%M[HK.LC(I^5F!!!_0=* +,L9DC*J[(?[RX
MR/SH ;;VXMT90S,6.XLQR2: &-91LK*0<-*LIY_B!!'\A0 @L8$>-DC";)#*
M-O&6(()/_?1H 0:=;!$'E@E-P5CU&[K0 /81LD(1Y(VA78KH>=N!D?H/RH <
MEE#$L"HI @&%&?;% $:Z7:K#-$J$)-)YK '&&XY'IT% $D%FL,C2EWDE8!=[
MG)P.W% #_LR?9Y8#G9)NW<_WLY_G0 GV9/.CEYWQH47GL<9_]!% $<%EY"[!
M/*T87:$8C 'Y4 *MC$C1LF5,<?E @\E?>@!(M-M8!#Y,*HT/W6 YZ8Y/?K0!
M-!;I;Q[$'R[F;GU))/ZF@!4A5)7D'WG !_#/^- &3K'AC3M<N(Y[P2%XUVKL
M?'&<T :EI;1V5G#:Q9\N% BY.3@# H FH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M (2K6?\ G[_\AK_A1[20>WJ!_P )5K/_ #]_^0U_PH]I(/;U _X2K6?^?O\
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M;U _X2K6?^?O_P AK_A1[20>WJ!_PE6L_P#/W_Y#7_"CVD@]O4#_ (2K6?\
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L]I(/;U _X2K6?^?O_P AK_A1[20>WJ!_PE6L_P#/U_Y#7_"GSR&J]1L__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
